Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H0KB
|
|||
| Former ID |
DAP000527
|
|||
| Drug Name |
Riluzole
|
|||
| Synonyms |
Rilutek; Riluzol; Riluzolum; Riluzole HCl; RP 54274; ALBB-006046; BF-37; PK-26124; R-116; RP-54274; Rilutek (TN); Riluzol [INN-Spanish]; Riluzole [USAN:INN]; Riluzolum [INN-Latin]; ZERO/001785; Amino-2 trifluoromethoxy-6 benzothiazole; Amino-2 trifluoromethoxy-6 benzothiazole [French]; Riluzole (JAN/USAN/INN); PK-26124, RP-54274, Rilutek, Riluzole; 2-Amino-6-(trifluoromethoxy)-benzothiazole; 2-Amino-6-(trifluoromethoxy)benzothiazole; 2-Amino-6-trifluoro-methoxybenzothiazole; 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole; 2-amino-6-(trifluoromethoxy)benzo[d]thiazole; 2-amino-6-(trifluoromethoxyl)benzothiazole; 2-amino-6-trifluoromethoxybenzothiazole; 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine; 6-(trifluoromethoxy)benzo[d]thiazol-2-amine; 6-Trifluoromethoxy-benzothiazol-2-ylamine; 6-trifluoromethoxybenzothiazole-2-yl-amine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Amyotrophic lateral sclerosis [ICD-11: 8B60.0; ICD-9: 335.2] | Approved | [1], [2] | |
| Therapeutic Class |
Anticonvulsants
|
|||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H5F3N2OS
|
|||
| Canonical SMILES |
C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N
|
|||
| InChI |
1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
|
|||
| InChIKey |
FTALBRSUTCGOEG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1744-22-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10139, 855844, 866566, 3158794, 7379879, 7735262, 7847840, 7980518, 8153119, 11111722, 11111723, 11113346, 11120296, 11120784, 11121272, 11466195, 11467315, 11484335, 11485690, 11488366, 12013649, 14773880, 17405620, 24278006, 26679689, 26751529, 29224139, 46508094, 47440015, 47515108, 47588789, 47810535, 47810536, 48034873, 48334245, 49698375, 49890627, 50100339, 50104104, 50104105, 53778170, 57322593, 57566695, 57641351, 74971764, 85089205, 85171908, 85231207, 85787918, 85788320
|
|||
| ChEBI ID |
CHEBI:8863
|
|||
| ADReCS Drug ID | BADD_D01942 | |||
| SuperDrug ATC ID |
N07XX02
|
|||
| SuperDrug CAS ID |
cas=001744225
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes indistinctus DSM22520
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Alistipes indistinctus DSM22520 (log2FC = -0.381; p = 0.01). | |||
|
Studied Microbe: Bacteroides caccae ATCC 43185
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides caccae ATCC 43185 (log2FC = -0.476; p = 0.039). | |||
|
Studied Microbe: Bacteroides dorei DSM 17855
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides dorei DSM 17855 (log2FC = -0.661; p = 0.002). | |||
|
Studied Microbe: Bacteroides eggerthii DSM20697
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides eggerthii DSM20697 (log2FC = -0.621; p = 0.009). | |||
|
Studied Microbe: Bacteroides fragilis ATCC43859
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis ATCC43859 (log2FC = -0.682; p = 0.018). | |||
|
Studied Microbe: Bacteroides fragilis HMW 610
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis HMW 610 (log2FC = -0.71; p = 0.008). | |||
|
Studied Microbe: Bacteroides fragilis HMW 615
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis HMW 615 (log2FC = -0.578; p = 0.039). | |||
|
Studied Microbe: Bacteroides fragilis NCTC 9343
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis NCTC 9343 (log2FC = -0.335; p = 0.011). | |||
|
Studied Microbe: Bacteroides fragilis str. 3397 T10
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis str. 3397 T10 (log2FC = -0.452; p = 0.022). | |||
|
Studied Microbe: Bacteroides fragilis str. 3986 T(B)9
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis str. 3986 T(B)9 (log2FC = -0.677; p = 0.005). | |||
|
Studied Microbe: Bacteroides fragilis str. DS-208
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides fragilis str. DS-208 (log2FC = -0.849; p = 0.001). | |||
|
Studied Microbe: Bacteroides ovatus ATCC 8483
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides ovatus ATCC 8483 (log2FC = -0.326; p = 0.019). | |||
|
Studied Microbe: Bacteroides stercoris ATCC 43183
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides stercoris ATCC 43183 (log2FC = -0.636; p = 0.004). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 3731
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides thetaiotaomicron 3731 (log2FC = -0.418; p = 0.016). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron 7330
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides thetaiotaomicron 7330 (log2FC = -0.552; p = 0.028). | |||
|
Studied Microbe: Bacteroides thetaiotaomicron VPI-5482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides thetaiotaomicron VPI-5482 (log2FC = -0.543; p = 0.005). | |||
|
Studied Microbe: Bacteroides uniformis ATCC 8492
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides uniformis ATCC 8492 (log2FC = -1.002; p = 0.003). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.532; p = 0.003). | |||
|
Studied Microbe: Bacteroides xylanisolvens DSM18836
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bacteroides xylanisolvens DSM18836 (log2FC = -0.751; p = 0.005). | |||
|
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Odoribacter splanchnicus (log2FC = -0.511; p = 0.021). | |||
|
Studied Microbe: Parabacteroides distasonis ATCC 8503
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Parabacteroides distasonis ATCC 8503 (log2FC = -0.561; p = 0.025). | |||
|
Studied Microbe: Pretovella copri DSM 18205
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Pretovella copri DSM 18205 (log2FC = -0.536; p = 0.005). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium ruminantium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Bifidobacterium ruminantium (log2FC = -0.581; p = 0.018). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Erysipelotrichales | ||||
|
Studied Microbe: Clostridium ramosum DSM 1402
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Clostridium ramosum DSM 1402 (log2FC = -0.464; p = 0.004). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia hansenii DSM20583
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Blautia hansenii DSM20583 (log2FC = -0.632; p = 0.004). | |||
|
Studied Microbe: Clostridium sp.
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Clostridium sp. (log2FC = -0.616; p = 0.002). | |||
|
Studied Microbe: Clostridium sporogenes ATCC 15579
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Clostridium sporogenes ATCC 15579 (log2FC = -0.45; p = 0.043). | |||
|
Studied Microbe: Roseburia intestinalis L1-82
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Roseburia intestinalis L1-82 (log2FC = -0.35; p = 0.033). | |||
|
Studied Microbe: Subdoligranulum variabile DSM 15176
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Subdoligranulum variabile DSM 15176 (log2FC = -0.362; p = 0.045). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Lactobacillus reuteri CF48-3A
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Lactobacillus reuteri CF48-3A (log2FC = -0.394; p = 0.011). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Verrucomicrobiales | ||||
|
Studied Microbe: Akkermansia muciniphila ATCC BAA-835
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Riluzole can be metabolized by Akkermansia muciniphila ATCC BAA-835 (log2FC = -0.461; p = 0.037). | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Riluzole hydrochloride (adjusted p-values: 9.14E-03). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Riluzole hydrochloride (adjusted p-values: 3.84E-04). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.9 (SCN11A) | Target Info | Blocker | [5] |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2326). | |||
| REF 2 | Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. | |||
| REF 3 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.